

1/37




FIG. 1

10 / 5 3 5 7 4 6

2/37




FIG. 2

10 / 5 3 5 7 4 6

3/37




FIG. 3

10/535746

4/37




FIG. 4A




FIG. 4B




FIG. 4C

FIG. 5A





FIG. 5B



5/37

FIG. 5D





FIG. 5C



10 / 5 3 5 7 4 6

6/37

10/535746

7/37




FIG. 6A




FIG. 6B




FIG. 6C




FIG. 6D

10/535748

8/37




FIG. 7C




FIG. 7B




FIG. 7D




FIG. 7F




FIG. 7E

10 / 535746

9/37




FIG. 8C



FIG. 8B




FIG. 8A

10/35746

10/37




FIG. 9

FIG. 10C




FIG. 10B





FIG. 10A



ANGIOGENIC REGULATORS WITHIN PLATELETS

(+) POSITIVE	(-) NEGATIVE
VEGF-A VEGF-C bFGF HGF	PF-4 THROMBOSPONDIN NK1, NK2, NK3 FRAGMENTS OF HGF TGF-BETA-1
ANGIOPOTETIN-1	PLASMINOGEN (ANGIOSTATIN) HIGH MOLECULAR WEIGHT KINININ (DOMAIN 5) FIBRONECTION (45 kD FRAGMENT)
PDGF EGF IGF-1 IGF BP-3	EGF (FRAGMENT) ALPHA-2 ANTIPLASMIN (FRAGMENT) BETA-THROMBOGLOBULIN ENDOSTATIN
VITRONECTIN FIBRONECTIN FIBRINOGEN HEPARANASE	SPHINGOSINE-1 PO ₄ BDNF (BRAIN DERIVED NEUROTROPHIC FACTOR)

FIG. 11

12/31 2002 46

10/535748

13/37




FIG. 12

10/535746

14/37




FIG. 13

10/535746

15/37

NON-ANGIOGENIC vs ANGIOGENIC HUMAN LIPOSARCOMA IN NUDE MICE.
LUCIFERASE LUMINESCENCE AT 133 DAYS.





FIG. 14



10 15 25 746

17/37

PROTEIN EXPRESSION MAPS OF EXTRACTS OF PLATELETS AND PLASMA
FROM SCID MICE BEARING NON-ANGIOGENIC AND ANGIOGENIC
HUMAN LIPOSARCOMAS, (30 DAYS AFTER TUMOR IMPLANTATION).




FIG. 16

10/15.25746

18/37

PROTEIN EXPRESSION MAPS OF EXTRACTS OF PLATELETS AND PLASMA FROM SCID MICE BEARING NON-ANGIOPERIC AND ANGIOGENIC HUMAN LIPOSARCOMAS, (30 DAYS AFTER TUMOR IMPLANTATION).




FIG. 17

10/09/97 46

19/37

PROTEIN EXPRESSION MAPS OF EXTRACTS OF PLATELETS AND PLASMA
FROM SCID MICE BEARING NON-ANGIOGENIC AND ANGIOGENIC
HUMAN LIPOSARCOMAS, (30 DAYS AFTER TUMOR IMPLANTATION).




FIG. 18

000 932 6 0747310000

23746

20/37

**NON-ANGIOPGENIC HUMAN LIPOSARCOMA (< 1mm.)
TIME COURSE OF SEQUESTRATION OF bFGF IN PLATELETS OF TUMOR-BEARING MICE.
ONLY MOLECULAR WEIGHT OF 1820 DALTONS INCLUDED.**




FIG. 19

10/535746

21/37




FIG. 20A

10/535746

22/37




FIG. 20B

10 15 35 746

23/37






FIG. 21A
FIG. 21B

10 / 535746

24/37

PLASMA PF4



PLATELET PF4




FIG. 21D

FIG. 21C

FIG. 22B






FIG. 22A



10 15 25 37 46

26/37

PLASMA PF4



PLATELET PF4




FIG. 22D

FIG. 22C

10/13/86 246

27/37




FIG. 23A

6005 932 1 04/20/85 10/15/85 C.R. 23B

28/37

PROTEIN EXPRESSION MAPS OF EXTRACTS OF PLATELETS AND PLASMA
FROM SCID MICE BEARING NON-ANGIOGENIC AND ANGIOGENIC
HUMAN LIPOSARCOMAS, (30 DAYS AFTER TUMOR IMPLANTATION).




FIG. 23B

10 / 535746

29/37




FIG. 24

10/535746

30/37




FIG. 25

10 / 535746

31/37




FIG. 26

10/1535746

32/37

VEGF ELISA




FIG. 27A

bFGF ELISA




FIG. 27B

10/15/57 46

33/37




FIG. 28

10/535746

34/37




FIG. 29A




FIG. 29B

2008.11.10. 10/533346

35/37




FIG. 29C




FIG. 29D

10/533746

432

36/37





FIG. 29E

FIG. 29F

10/15/33746

37/37




FIG. 29H




FIG. 29G

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.